A carregar...
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). In recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development due to either toxicity or lack of benefit. Recently, data of the RE...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5036543/ https://ncbi.nlm.nih.gov/pubmed/27703962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S112537 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|